APOE and early-onset autosomal dominant Alzheimer disease: As expected, APOE Ɛ4 dosage was significantly and positively associated with the risk of incident vascular dementia (2 vs. 0; adjusted HR: 5.81; 95%CI: 4.72, 7.15), and incident Alzheimer’s disease (2 vs. 0; adjusted HR: 12.05; 95%CI: 10.54, 13.77) (Supplementary Table 2).